

Neurotech

20 May 2021

Appointment of Allan Cripps as Non-Executive Director

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") is pleased to advise that Professor Allan Cripps AO has been appointed as non-executive director, effective from 19 May 2021.

Professor Cripps is currently a Professor Emeritus in the School of Medicine and Dentistry and the Menzies Health Institute Queensland at Griffith University, Australia. He is a member of the Infection and Immunity Research Team at the Menzies Health Institute Queensland at Griffith University, Australia. He is recognised nationally and internationally as a distinguished academic, clinical scientist and health services leader and has made significant contributions in immunology, vaccine development, diagnostics health services delivery and professional health education. The focus of Professor Cripps' research activities over the last 5 decades have been in the field of immunology and inflammation. In 2015 he was awarded an Officer of the Order of Australia (AO) in recognition of his contributions to mucosal immunization, public health and higher education.

Professor Cripps has experience in the development of immunity in children and mucosal immune mechanisms, in recent years he has made a significant contribution to the field of immunology through translational research and human clinical studies. Professor Cripps is also a co-inventor on several patents in the fields of diagnostic technology and vaccine protein antigens for respiratory infection. He has published over 325 peer reviewed scientific papers and presented at many national and international scientific conferences.

In 2012 he launched the first international peer-reviewed journal exclusively focused on pneumonia as a means for bringing together knowledge related to pathogenesis, treatment and prevention of this disease and remains the Journal's Founding Editor. Pneumonia is the single largest cause of death in children globally.

Professor Cripps is a member of journal VACCINE Council of 100. This Council is made up of 100 of the world's leading vaccine researchers and clinicians and provides advice on vaccine development to both the Journal and other organisations globally. He is also a member of the Immunisation Coalition and a member of the Coalition's Scientific Advisory Committee and is currently appointed to industry advisory boards for advice on strategies related to the development of vaccines for respiratory infections in children and adults including those with chronic lung conditions.

"I am very pleased to have a scientist of the calibre of Professor Cripps joining the board of Neurotech at such an important juncture in the company's transition from preclinical to clinical studies", said Brian Leedman, Chairman of Neurotech International. "His appointment fills an obvious void in the board's collective experience as the company increases expenditure in the scientific research of our unique cannabis strains for the treatment of neurological disorders".

Professor Cripps said "I am honoured to be joining the Board of Neurotech International at this exciting time

as clinical research is commencing with low level THC cannabis plant strains, initially in children with Autism and with potential broader application of these strains in other neurological and inflammatory disorders”.

As part of his appointment, the Company has agreed to seek shareholder approval for a grant of 500,000 options to Professor Cripps, with a 9c exercise price and expiring on 12 May 2023.

Authority

This announcement has been authorised for release by the Board of the Company.

Further Information

Brian Leedman
Chairman
+61 41 228 1780

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 410 667 844

About Neurotech

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit <http://www.neurotechinternational.com>